Trial Profile
Study of daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 07 Jun 2018 New trial record